or Try an Advanced Search...

    ETF Components for SBIO - ALPS Medical Breakthroughs ETF


    Below is a list of stocks held by this ETF. We only list holdings in the same market. If this is a global ETF, there may be additional components other than those listed here.

    Holdings

    Symbol Grade Price % Change Allocation
    CORT B -5.40 3.70
    KRYS D -3.75 3.48
    ACLX C -7.63 3.29
    RNA C -15.59 3.21
    CRNX C -8.28 2.87
    ALKS B -0.56 2.84
    IMVT D -5.06 2.70
    DNLI C -11.95 2.60
    MRUS D -6.20 2.27
    PTCT B -7.43 2.01
    XENE D -4.60 2.00
    AGIO B -2.92 1.98
    EWTX C -4.35 1.95
    FOLD F -4.06 1.94
    VRNA B 0.82 1.88
    ZLAB C 1.46 1.78
    ACAD C -1.47 1.75
    CGON D -7.34 1.68
    VERA B -5.59 1.66
    PTGX D 0.17 1.60
    IDYA F -9.60 1.58
    VCEL A -0.49 1.56
    GERN F -1.35 1.51
    KROS C -6.18 1.48
    AKRO C -5.61 1.42
    LBPH A -0.08 1.24
    MIRM A -3.80 1.22
    MNKD B -3.13 1.19
    IRON C -1.99 1.16
    TARS B -3.90 1.13
    SNDX D -5.72 1.13
    ARVN D -9.79 1.13
    GLPG F -3.94 1.05
    CLDX F -8.51 1.04
    IMCR D -3.16 1.04
    NTLA F -7.61 0.99
    BCRX D -5.64 0.96
    RCUS F -0.44 0.95
    SPRY C -0.71 0.94
    VRDN C -6.93 0.92
    XNCR B -1.83 0.89
    DAWN D -7.05 0.89
    KURA F -3.46 0.81
    PHVS D -0.97 0.75
    APLT C -3.55 0.74
    COGT D -7.77 0.70
    AUPH B -2.52 0.70
    ETNB D -9.37 0.66
    PRTA F -12.98 0.57
    PLRX D -3.27 0.56
    LQDA F -1.85 0.53
    ERAS C -4.98 0.53
    REPL C -5.26 0.51
    AVXL C -7.29 0.46
    IRWD D 2.43 0.45
    OLMA F -9.21 0.44
    MLYS D -5.67 0.42
    ANNX D -3.32 0.42
    ALLO D -7.72 0.42
    YMAB D -3.88 0.41
    SVRA F -6.58 0.40
    CELC F -10.28 0.37
    ANAB F -5.80 0.36
    ALEC F -17.21 0.35
    FLGT F -2.70 0.35
    ALT C -9.99 0.33
    ARCT F -12.65 0.33
    FULC F -9.49 0.33
    URGN F -5.65 0.32
    AURA C -5.02 0.30
    GHRS C 1.34 0.26
    TBPH B -0.52 0.26
    FDMT F 10.10 0.25
    STRO D -16.23 0.22
    CMPS F 3.07 0.22
    ALDX F -1.41 0.20
    ACIU D -10.14 0.19
    ITOS F -2.72 0.19
    VNDA C -1.96 0.18
    ZNTL D -12.15 0.17
    ENTA F -5.92 0.14
    INZY F -8.89 0.14
    HLVX D -3.17 0.06

    Represented by ETF Holdings

    Keywords: Biopharmaceutical Medicine Biotechnology Cancer Biology Clinical Medicine Life Sciences Organ Systems Disease Immunology Antibodies Autoimmune Disease Clinical Development Immune System Chemical Compounds Monoclonal Antibodies Neurological Disorders Rare Diseases Solid Tumors Alcohol
    Industries: Biotechnology Diagnostics & Research Drug Manufacturers - Specialty & Generic Medical Care Facilities

    Recent News for ALPS Medical Breakthroughs ETF & its Holdings

    Date Stock Title
    Nov 15 SNDX Syndax wins FDA approval for leukemia drug revumenib
    Nov 15 SNDX Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation
    Nov 15 ACIU AC Immune’s stock jumps after Parkinson’s therapy shows signs of benefit
    Nov 15 AKRO Akero Therapeutics to Showcase New Analyses of Phase 2b HARMONY Study in Presentations at 75th Annual AASLD The Liver Meeting® 2024
    Nov 15 ALT Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024
    Nov 15 LQDA Liquidia Corporation: Resilience In The Face Of Formidable Opposition Can Pay Off
    Nov 15 ERAS Erasca (ERAS) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
    Nov 15 PRTA Biogen Partner Eisai Gets Positive CHMP Nod for Leqembi in Europe
    Nov 15 CRNX Crinetics Pharmaceuticals to Participate in Three Upcoming December Investor Conferences
    Nov 15 IDYA Jim Cramer Says This Tobacco Stock Is 'Undervalued' But He's Not Recommending It
    Nov 15 ITOS iTeos Therapeutics, Inc. (NASDAQ:ITOS) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year
    Nov 15 TARS Tarsus Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations
    Nov 15 DNLI We're Hopeful That Denali Therapeutics (NASDAQ:DNLI) Will Use Its Cash Wisely
    Nov 15 MIRM Analysts Are Updating Their Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Estimates After Its Third-Quarter Results
    Nov 15 ETNB 89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting® 2024
    Nov 15 ACIU AC Immune reports interim results from Phase 2 trial of ACI-7104.056
    Nov 15 FULC Fulcrum Therapeutics Third Quarter 2024 Earnings: US$0.35 loss per share (vs US$0.39 loss in 3Q 2023)
    Nov 15 SPRY Loss-Making ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Expected To Breakeven In The Medium-Term
    Nov 15 STRO Sutro Biopharma Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
    Nov 15 CMPS RFK and the 'MAHA Trade': Vaccine makers down, psychedelic shares up
    The investment seeks investment results that correspond (before fees and expenses) generally to the performance of its underlying index, the Poliwogg Medical Breakthroughs IndexSM. The fund employs a "passive management" - or indexing - investment approach designed to track the performance of the underlying index. It will normally invest at least 80% of its net assets in securities that comprise the underlying index. The underlying index is comprised of small- and mid-cap stocks of biotechnology and pharmaceutical companies that have one or more drugs in either Phase II or Phase III U.S. Food and Drug Administration clinical trials. It is non-diversified.
    Exchange Traded Fund ETF Index Fund Biotechnology Pharmaceutical Passive Management
    Back to the Main SBIO Page...